These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 19350467)
1. Circumventing immunogenicity in the development of therapeutic antibodies. Holgate RG; Baker MP IDrugs; 2009 Apr; 12(4):233-7. PubMed ID: 19350467 [TBL] [Abstract][Full Text] [Related]
2. Prediction of immunogenicity for therapeutic proteins: state of the art. De Groot AS; Moise L Curr Opin Drug Discov Devel; 2007 May; 10(3):332-40. PubMed ID: 17554860 [TBL] [Abstract][Full Text] [Related]
3. Can we prevent immunogenicity of human protein drugs? Scott DW; De Groot AS Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i72-76. PubMed ID: 19995750 [TBL] [Abstract][Full Text] [Related]
4. De-immunization of therapeutic proteins by T-cell epitope modification. De Groot AS; Knopp PM; Martin W Dev Biol (Basel); 2005; 122():171-94. PubMed ID: 16375261 [TBL] [Abstract][Full Text] [Related]
5. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Koren E; De Groot AS; Jawa V; Beck KD; Boone T; Rivera D; Li L; Mytych D; Koscec M; Weeraratne D; Swanson S; Martin W Clin Immunol; 2007 Jul; 124(1):26-32. PubMed ID: 17490912 [TBL] [Abstract][Full Text] [Related]
6. [Immunogenicity of therapeutic antibodies]. Stas P; Lasters I Med Sci (Paris); 2009 Dec; 25(12):1070-7. PubMed ID: 20035681 [TBL] [Abstract][Full Text] [Related]
7. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem. Ulitzka M; Carrara S; Grzeschik J; Kornmann H; Hock B; Kolmar H Protein Eng Des Sel; 2020 Sep; 33():. PubMed ID: 33128053 [TBL] [Abstract][Full Text] [Related]
8. Reflections on the immunogenicity of therapeutic proteins. Antonelli G Clin Microbiol Infect; 2008 Aug; 14(8):731-3. PubMed ID: 18325035 [TBL] [Abstract][Full Text] [Related]
9. Deimmunization of monoclonal antibodies. Jones TD; Crompton LJ; Carr FJ; Baker MP Methods Mol Biol; 2009; 525():405-23, xiv. PubMed ID: 19252848 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of protein therapeutics. De Groot AS; Scott DW Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218 [TBL] [Abstract][Full Text] [Related]
14. Overcoming immunogenicity associated with the use of biopharmaceuticals. Tovey MG; Legrand J; Lallemand C Expert Rev Clin Pharmacol; 2011 Sep; 4(5):623-31. PubMed ID: 22114889 [TBL] [Abstract][Full Text] [Related]
15. Considerations for the development of therapeutic monoclonal antibodies. Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093 [TBL] [Abstract][Full Text] [Related]
16. 8-1A, a human monoclonal antibody that reacts with intact human chorionic gonadotropin. Suzuki N; Aoki D; Orikawa K; Suzuki A; Susumu N; Tamada Y; Sakayori M; Tsukazaki K; Mukai M; Kikuchi H; Ishida I; Nozawa S Placenta; 2006; 27(2-3):333-9. PubMed ID: 16338478 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. Barbosa MD; Celis E Drug Discov Today; 2007 Aug; 12(15-16):674-81. PubMed ID: 17706550 [TBL] [Abstract][Full Text] [Related]
18. [Monoclonals antibodies: a recent and major therapeutic advance]. Paintaud G; Lejarre F; Ternant D; Goupille P; Watier H Therapie; 2009; 64(1):1-7. PubMed ID: 19463247 [TBL] [Abstract][Full Text] [Related]
19. Molecular engineering and design of therapeutic antibodies. Presta LG Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541 [TBL] [Abstract][Full Text] [Related]
20. Identification and removal of immunogenicity in therapeutic proteins. Baker MP; Jones TD Curr Opin Drug Discov Devel; 2007 Mar; 10(2):219-27. PubMed ID: 17436557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]